Aquestive Therapeutics (NASDAQ:AQST) Upgraded by Zacks Investment Research to “Hold”

Aquestive Therapeutics (NASDAQ:AQSTGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States. “

Several other equities analysts have also recently weighed in on the company. Wedbush lowered their target price on Aquestive Therapeutics from $26.00 to $8.00 and set an “outperform” rating on the stock in a research note on Thursday, March 10th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Aquestive Therapeutics in a research note on Thursday, December 23rd.

AQST traded up $0.03 during trading on Wednesday, reaching $2.12. The company had a trading volume of 4,058 shares, compared to its average volume of 386,561. The firm’s 50-day simple moving average is $2.57 and its 200 day simple moving average is $3.82. The company has a market cap of $87.91 million, a price-to-earnings ratio of -1.15 and a beta of 3.30. Aquestive Therapeutics has a 12-month low of $1.91 and a 12-month high of $6.40.

Aquestive Therapeutics (NASDAQ:AQSTGet Rating) last issued its quarterly earnings results on Tuesday, March 8th. The company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01). The company had revenue of $11.08 million during the quarter, compared to analysts’ expectations of $9.81 million. During the same quarter in the prior year, the company earned ($0.60) earnings per share. Analysts anticipate that Aquestive Therapeutics will post -1.64 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of AQST. Morgan Stanley raised its holdings in shares of Aquestive Therapeutics by 54.7% during the 2nd quarter. Morgan Stanley now owns 553,727 shares of the company’s stock valued at $2,198,000 after purchasing an additional 195,685 shares in the last quarter. IndexIQ Advisors LLC raised its holdings in shares of Aquestive Therapeutics by 11.1% during the 3rd quarter. IndexIQ Advisors LLC now owns 86,461 shares of the company’s stock valued at $377,000 after purchasing an additional 8,660 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Aquestive Therapeutics by 7.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 73,165 shares of the company’s stock valued at $319,000 after purchasing an additional 5,135 shares in the last quarter. Jump Financial LLC raised its holdings in shares of Aquestive Therapeutics by 62.3% during the 3rd quarter. Jump Financial LLC now owns 49,700 shares of the company’s stock valued at $216,000 after purchasing an additional 19,070 shares in the last quarter. Finally, GSA Capital Partners LLP raised its holdings in shares of Aquestive Therapeutics by 203.9% during the 3rd quarter. GSA Capital Partners LLP now owns 297,229 shares of the company’s stock valued at $1,296,000 after purchasing an additional 199,428 shares in the last quarter. 39.17% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile (Get Rating)

Aquestive Therapeutics, Inc, a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Recommended Stories

Get a free copy of the Zacks research report on Aquestive Therapeutics (AQST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.